PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 132 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is 0.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $15,001,000 | -21.3% | 399,496 | 0.0% | 3.16% | +15.8% |
Q2 2017 | $19,056,000 | +4.6% | 399,496 | 0.0% | 2.73% | +9.2% |
Q1 2017 | $18,217,000 | -27.3% | 399,496 | -48.5% | 2.50% | -45.4% |
Q4 2016 | $25,045,000 | -5.6% | 775,388 | 0.0% | 4.58% | -5.4% |
Q3 2016 | $26,534,000 | +1.5% | 775,388 | 0.0% | 4.84% | +36.2% |
Q2 2016 | $26,154,000 | -38.9% | 775,388 | -4.0% | 3.55% | -16.8% |
Q1 2016 | $42,789,000 | -24.7% | 807,650 | +9.1% | 4.27% | +7.8% |
Q4 2015 | $56,825,000 | +94.7% | 740,000 | +4.2% | 3.96% | +92.3% |
Q3 2015 | $29,181,000 | -4.2% | 710,000 | +64.9% | 2.06% | +19.6% |
Q2 2015 | $30,447,000 | +21.4% | 430,535 | +52.5% | 1.72% | +12.0% |
Q1 2015 | $25,081,000 | +1755.1% | 282,284 | +1750.8% | 1.54% | +2037.5% |
Q4 2014 | $1,352,000 | +143.2% | 15,252 | +166.1% | 0.07% | +140.0% |
Q3 2014 | $556,000 | +5.5% | 5,732 | 0.0% | 0.03% | -9.1% |
Q2 2014 | $527,000 | -39.1% | 5,732 | -53.6% | 0.03% | -59.3% |
Q1 2014 | $865,000 | +64.1% | 12,366 | +35.0% | 0.08% | +107.7% |
Q4 2013 | $527,000 | – | 9,160 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |